Recent Advances with Precision Medicine Treatment for Breast Cancer including Triple-Negative Sub-Type

Breast cancer is a heterogeneous disease with different molecular subtypes. Breast cancer is the second leading cause of mortality in woman due to rapid metastasis and disease recurrence. Precision medicine remains an essential source to lower the off-target toxicities of chemotherapeutic agents and maximize the patient benefits. This is a crucial approach for a more effective treatment and prevention of disease. Precision-medicine methods are based on the selection of suitable biomarkers to envision the effectiveness of targeted therapy in a specific group of patients. Several druggable mutations have been identified in breast cancer patients. Current improvements in omics technologies have focused on more precise strategies for precision therapy. The development of next-generation sequencing technologies has raised hopes for precision-medicine treatment strategies in breast cancer (BC) and triple-negative breast cancer (TNBC). Targeted therapies utilizing immune checkpoint inhibitors (ICIs), epidermal growth factor receptor inhibitor (EGFRi), poly(ADP-ribose) polymerase inhibitor (PARPi), antibody–drug conjugates (ADCs), oncolytic viruses (OVs), glucose transporter-1 inhibitor (GLUT1i), and targeting signaling pathways are potential treatment approaches for BC and TNBC. This review emphasizes the recent progress made with the precision-medicine therapy of metastatic breast cancer and TNBC.

[1]  B. Czerniecki,et al.  Oncolytic T-VEC virotherapy plus neoadjuvant chemotherapy in nonmetastatic triple-negative breast cancer: a phase 2 trial , 2023, Nature Medicine.

[2]  A. Puri,et al.  Recent Advances in Targeted Nanocarriers for the Management of Triple Negative Breast Cancer , 2023, Pharmaceutics.

[3]  L. Mariani,et al.  Efficacy and Safety of First-line Carboplatin-paclitaxel and Carboplatin-gemcitabine in Patients With Advanced Triple-negative Breast Cancer: A Monocentric, Retrospective Comparison. , 2022, Clinical breast cancer.

[4]  L. Carey,et al.  Immunotherapy in triple negative breast cancer: beyond checkpoint inhibitors , 2022, npj Breast Cancer.

[5]  N. Koutsouleris,et al.  From promise to practice: towards the realisation of AI-informed mental health care. , 2022, The Lancet. Digital health.

[6]  Rita Almeida Ribeiro,et al.  Immunotherapy in triple-negative breast cancer: Insights into tumor immune landscape and therapeutic opportunities , 2022, Frontiers in Molecular Biosciences.

[7]  P. Millner,et al.  Hyaluronic-Acid-Tagged Cubosomes Deliver Cytotoxics Specifically to CD44-Positive Cancer Cells , 2022, Molecular pharmaceutics.

[8]  J. Abraham,et al.  Precision Breast Cancer Medicine: Early Stage Triple Negative Breast Cancer—A Review of Molecular Characterisation, Therapeutic Targets and Future Trends , 2022, Frontiers in Oncology.

[9]  S. Loi,et al.  Pembrolizumab plus Chemotherapy in Advanced Triple-Negative Breast Cancer. , 2022, The New England journal of medicine.

[10]  B. Kiesewetter,et al.  Applicability of ESMO-MCBS and ESCAT for molecular tumor boards , 2022, memo - Magazine of European Medical Oncology.

[11]  J. Garber,et al.  PARP inhibition in breast cancer: progress made and future hopes , 2022, NPJ breast cancer.

[12]  H. Gómez,et al.  Immunotherapy in triple-negative breast cancer: A literature review and new advances , 2022, World journal of clinical oncology.

[13]  D. Jayne,et al.  Affimer Tagged Cubosomes: Targeting of Carcinoembryonic Antigen Expressing Colorectal Cancer Cells Using In Vitro and In Vivo Models , 2022, ACS applied materials & interfaces.

[14]  H. Rugo,et al.  Immunotherapy for early triple negative breast cancer: research agenda for the next decade , 2022, NPJ breast cancer.

[15]  Fan Yang,et al.  Comprehensive metabolomics expands precision medicine for triple-negative breast cancer , 2022, Cell Research.

[16]  A. Hartkopf,et al.  Clinical Trials of Oncolytic Viruses in Breast Cancer , 2021, Frontiers in Oncology.

[17]  S. Tomao,et al.  Emerging Role of PARP Inhibitors in Metastatic Triple Negative Breast Cancer. Current Scenario and Future Perspectives , 2021, Frontiers in Oncology.

[18]  D. Singh,et al.  Role of PARP in TNBC: Mechanism of Inhibition, Clinical Applications, and Resistance , 2021, Biomedicines.

[19]  Frederick M. Howard,et al.  The emerging role of immune checkpoint inhibitors for the treatment of breast cancer , 2021, Expert opinion on investigational drugs.

[20]  P. Fasching,et al.  VP7-2021: KEYNOTE-522: Phase III study of neoadjuvant pembrolizumab + chemotherapy vs. placebo + chemotherapy, followed by adjuvant pembrolizumab vs. placebo for early-stage TNBC , 2021 .

[21]  A. Schneeweiss,et al.  First-line atezolizumab plus nab-paclitaxel for unresectable, locally advanced, or metastatic triple-negative breast cancer: IMpassion130 final overall survival analysis. , 2021, Annals of oncology : official journal of the European Society for Medical Oncology.

[22]  L. Miele,et al.  Precision Medicine and Triple-Negative Breast Cancer: Current Landscape and Future Directions , 2021, Cancers.

[23]  A. Tan,et al.  Combination of Pertuzumab and Trastuzumab in the Treatment of HER2-Positive Early Breast Cancer: A Review of the Emerging Clinical Data , 2021, Breast cancer.

[24]  R. Gelber,et al.  Adjuvant Olaparib for Patients with BRCA1- or BRCA2-Mutated Breast Cancer. , 2021, The New England journal of medicine.

[25]  G. Curigliano,et al.  Precision medicine in breast cancer: From clinical trials to clinical practice. , 2021, Cancer treatment reviews.

[26]  M. Piccart,et al.  Sacituzumab Govitecan in Metastatic Triple-Negative Breast Cancer. , 2021, The New England journal of medicine.

[27]  C. Kelly,et al.  Overview of recent advances in metastatic triple negative breast cancer , 2021, World journal of clinical oncology.

[28]  R. Barroso-Sousa,et al.  Clinical Development of New Antibody–Drug Conjugates in Breast Cancer: To Infinity and Beyond , 2021, BioDrugs.

[29]  Xinchen Wang,et al.  BKM120 sensitizes BRCA-proficient triple negative breast cancer cells to olaparib through regulating FOXM1 and Exo1 expression , 2021, Scientific Reports.

[30]  Ying Cheng,et al.  Pyrotinib plus capecitabine versus lapatinib plus capecitabine for the treatment of HER2-positive metastatic breast cancer (PHOEBE): a multicentre, open-label, randomised, controlled, phase 3 trial. , 2021, The Lancet. Oncology.

[31]  A. Jemal,et al.  Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries , 2021, CA: a cancer journal for clinicians.

[32]  A. Barry,et al.  Role of radiation therapy in triple negative breast cancer: current state and future directions—a narrative review , 2021, Precision Cancer Medicine.

[33]  J. Crabtree,et al.  Targeting Notch in oncology: the path forward , 2020, Nature Reviews Drug Discovery.

[34]  Ahn， Jin Hee,et al.  Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer (KEYNOTE-355): a randomised, placebo-controlled, double-blind, phase 3 clinical trial , 2020, The Lancet.

[35]  F. Cardoso,et al.  Third-line treatment of HER2-positive advanced breast cancer: From no standard to a Pandora's box. , 2020, Biochimica et biophysica acta. Reviews on cancer.

[36]  K. Kalinsky,et al.  Antibody-drug conjugates in metastatic triple negative breast cancer: a spotlight on sacituzumab govitecan, ladiratuzumab vedotin, and trastuzumab deruxtecan , 2020, Expert opinion on biological therapy.

[37]  J. Pérez-García,et al.  CDK4/6 Inhibitors in Hormone Receptor-Positive Metastatic Breast Cancer: Current Practice and Knowledge , 2020, Cancers.

[38]  E. Petricoin,et al.  Perspectives on Triple-Negative Breast Cancer: Current Treatment Strategies, Unmet Needs, and Potential Targets for Future Therapies , 2020, Cancers.

[39]  W. Eiermann,et al.  Talazoparib versus chemotherapy in patients with germline BRCA1/2-mutated HER2-negative advanced breast cancer: final overall survival results from the EMBRACA trial. , 2020, Annals of oncology : official journal of the European Society for Medical Oncology.

[40]  D. Slamon,et al.  Targeting activated PI3K/mTOR signaling overcomes acquired resistance to CDK4/6-based therapies in preclinical models of hormone receptor-positive breast cancer , 2020, Breast Cancer Research.

[41]  J. Abraham,et al.  Novel HER2–targeted therapies for HER2–positive metastatic breast cancer , 2020, Cancer.

[42]  Xin Hu,et al.  Molecular subtyping and genomic profiling expand precision medicine in refractory metastatic triple-negative breast cancer: the FUTURE trial , 2020, Cell Research.

[43]  J. Aster,et al.  Pharmacological disruption of the Notch transcription factor complex , 2020, Proceedings of the National Academy of Sciences.

[44]  H. Olzscha,et al.  Impact of HDAC Inhibitors on Protein Quality Control Systems: Consequences for Precision Medicine in Malignant Disease , 2020, Frontiers in Cell and Developmental Biology.

[45]  G. Arpino,et al.  Second line trastuzumab emtansine following horizontal dual blockade in a real-life setting , 2020, Oncotarget.

[46]  P. Fasching,et al.  Tumor mutational burden and immune infiltration as independent predictors of response to neoadjuvant immune checkpoint inhibition in early TNBC in GeparNuevo. , 2020, Annals of oncology : official journal of the European Society for Medical Oncology.

[47]  A. Cervantes,et al.  Personalized Medicine: Recent Progress in Cancer Therapy , 2020, Cancers.

[48]  J. Mielgo-Ayuso,et al.  Liquid Biopsy as Novel Tool in Precision Medicine: Origins, Properties, Identification and Clinical Perspective of Cancer’s Biomarkers , 2020, Diagnostics.

[49]  P. Fasching,et al.  Pembrolizumab for Early Triple-Negative Breast Cancer. , 2020, The New England journal of medicine.

[50]  C. Redfern,et al.  Antitumor Activity and Safety of Trastuzumab Deruxtecan in Patients With HER2-Low–Expressing Advanced Breast Cancer: Results From a Phase Ib Study , 2020, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[51]  David Killock.  AKT inhibition improves OS in TNBC , 2020, Nature Reviews Clinical Oncology.

[52]  B. Haibe-Kains,et al.  GLUT1 inhibition blocks growth of RB1-positive triple negative breast cancer , 2019, Nature Communications.

[53]  D. Gewirtz,et al.  Roles of autophagy in breast cancer treatment: target, bystander or benefactor. , 2019, Seminars in cancer biology.

[54]  E. Winer,et al.  Atezolizumab plus nab-paclitaxel as first-line treatment for unresectable, locally advanced or metastatic triple-negative breast cancer (IMpassion130): updated efficacy results from a randomised, double-blind, placebo-controlled, phase 3 trial. , 2019, The Lancet. Oncology.

[55]  B. Dong,et al.  Advances and perspectives of PARP inhibitors , 2019, Experimental Hematology & Oncology.

[56]  Jack Junjie Chan,et al.  Novel therapeutic avenues in triple-negative breast cancer: PI3K/AKT inhibition, androgen receptor blockade, and beyond , 2019, Therapeutic advances in medical oncology.

[57]  J. Mejia,et al.  KEYNOTE-119: Phase III study of pembrolizumab (pembro) versus single-agent chemotherapy (chemo) for metastatic triple negative breast cancer (mTNBC) , 2019, Annals of Oncology.

[58]  P. Steeg,et al.  Antibody–drug conjugates for cancer , 2019, The Lancet.

[59]  S. Loi,et al.  Triple-negative breast cancer: recent treatment advances , 2019, F1000Research.

[60]  H. Han,et al.  Advanced drug delivery system with nanomaterials for personalised medicine to treat breast cancer , 2019, Journal of Drug Delivery Science and Technology.

[61]  M. V. Giuli,et al.  Notch Signaling Activation as a Hallmark for Triple-Negative Breast Cancer Subtype , 2019, Journal of oncology.

[62]  F. Bertucci,et al.  PD-1/PD-L1 Targeting in Breast Cancer: The First Clinical Evidences are Emerging—A Literature Review , 2019, Cancers.

[63]  W. Gradishar,et al.  SOPHIA primary analysis: A phase 3 (P3) study of margetuximab (M) + chemotherapy (C) versus trastuzumab (T) + C in patients (pts) with HER2+ metastatic (met) breast cancer (MBC) after prior anti-HER2 therapies (Tx). , 2019, Journal of Clinical Oncology.

[64]  G. Curigliano,et al.  Recent advances in triple negative breast cancer: the immunotherapy era , 2019, BMC Medicine.

[65]  M. Lux,et al.  Preliminary safety and efficacy of first-line pertuzumab combined with trastuzumab and taxane therapy for HER2-positive locally recurrent or metastatic breast cancer (PERUSE). , 2019, Annals of oncology : official journal of the European Society for Medical Oncology.

[66]  A. Bardia,et al.  Sacituzumab Govitecan‐hziy in Refractory Metastatic Triple‐Negative Breast Cancer , 2019, The New England journal of medicine.

[67]  S. Mallal,et al.  Correction: RAS/MAPK Activation Is Associated with Reduced Tumor-Infiltrating Lymphocytes in Triple-Negative Breast Cancer: Therapeutic Cooperation Between MEK and PD-1/PD-L1 Immune Checkpoint Inhibitors , 2019, Clinical Cancer Research.

[68]  Eric P. Winer,et al.  Breast Cancer Treatment: A Review , 2019, JAMA.

[69]  Guojun Wu,et al.  Disulfiram and BKM120 in Combination with Chemotherapy Impede Tumor Progression and Delay Tumor Recurrence in Tumor Initiating Cell-Rich TNBC , 2019, Scientific Reports.

[70]  Heikki Joensuu,et al.  Tumor-Infiltrating Lymphocytes and Prognosis: A Pooled Individual Patient Analysis of Early-Stage Triple-Negative Breast Cancers. , 2019, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[71]  J. Crabtree,et al.  Notch Signaling Regulates Mitochondrial Metabolism and NF-κB Activity in Triple-Negative Breast Cancer Cells via IKKα-Dependent Non-canonical Pathways , 2018, Front. Oncol..

[72]  S. Barni,et al.  A multicenter REtrospective observational study of first-line treatment with PERtuzumab, trastuzumab and taxanes for advanced HER2 positive breast cancer patients. RePer Study , 2018, Cancer biology & therapy.

[73]  E. Winer,et al.  Atezolizumab and Nab‐Paclitaxel in Advanced Triple‐Negative Breast Cancer , 2018, The New England journal of medicine.

[74]  Hui Zhao,et al.  Antitumor effects and mechanisms of olaparib in combination with carboplatin and BKM120 on human triple-negative breast cancer cells , 2018, Oncology reports.

[75]  W. Eiermann,et al.  Talazoparib in Patients with Advanced Breast Cancer and a Germline BRCA Mutation , 2018, The New England journal of medicine.

[76]  Jun Zhang,et al.  Precision medicine based on tumorigenic signaling pathways for triple-negative breast cancer , 2018, Oncology letters.

[77]  F. Lobelo,et al.  The Limits and Potential Future Applications of Personalized Medicine to Prevent Complex Chronic Disease , 2018, Public health reports.

[78]  K. J. Hamblett,et al.  Abstract 3914: ZW49, a HER2-targeted biparatopic antibody-drug conjugate for the treatment of HER2-expressing cancers , 2018, Experimental and Molecular Therapeutics.

[79]  F. Puglisi,et al.  Androgen receptor in triple negative breast cancer: A potential target for the targetless subtype. , 2018, Cancer treatment reviews.

[80]  D. Goldenberg,et al.  The emergence of trophoblast cell-surface antigen 2 (TROP-2) as a novel cancer target , 2018, Oncotarget.

[81]  J. Ajani,et al.  Single agent activity of ZW25, a HER2-targeted bispecific antibody, in heavily pretreated HER2-expressing cancers. , 2018 .

[82]  Y. Naito,et al.  Precision medicine in breast cancer. , 2018, Chinese clinical oncology.

[83]  L. Carey,et al.  Evolution of Targeted Therapy in Breast Cancer: Where Precision Medicine Began. , 2018, American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting.

[84]  W. Kibbe,et al.  Complexity of Delivering Precision Medicine: Opportunities and Challenges. , 2018, American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting.

[85]  D. Kwapisz.  Cyclin-dependent kinase 4/6 inhibitors in hormone receptor-positive early breast cancer: preliminary results and ongoing studies , 2018, Breast Cancer.

[86]  E. Fattal,et al.  Aptamer‐guided siRNA‐loaded nanomedicines for systemic gene silencing in CD‐44 expressing murine triple‐negative breast cancer model , 2018, Journal of controlled release : official journal of the Controlled Release Society.

[87]  P. Lønning,et al.  Buparlisib plus fulvestrant in postmenopausal women with hormone-receptor-positive, HER2-negative, advanced breast cancer progressing on or after mTOR inhibition (BELLE-3): a randomised, double-blind, placebo-controlled, phase 3 trial. , 2018, The Lancet. Oncology.

[88]  A. Chinnaiyan,et al.  Comprehensive Mutation and Copy Number Profiling in Archived Circulating Breast Cancer Tumor Cells Documents Heterogeneous Resistance Mechanisms. , 2018, Cancer research.

[89]  Xin Li,et al.  Discovery and development of pyrotinib: A novel irreversible EGFR/HER2 dual tyrosine kinase inhibitor with favorable safety profiles for the treatment of breast cancer , 2017, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

[90]  J. Bergh,et al.  RESILIENCE: Phase III Randomized, Double‐Blind Trial Comparing Sorafenib With Capecitabine Versus Placebo With Capecitabine in Locally Advanced or Metastatic HER2‐Negative Breast Cancer , 2017, Clinical breast cancer.

[91]  U. Nir,et al.  Mitochondrial OXPHOS Induced by RB1 Deficiency in Breast Cancer: Implications for Anabolic Metabolism, Stemness, and Metastasis. , 2017, Trends in cancer.

[92]  M. Goetz,et al.  MONARCH 3: Abemaciclib As Initial Therapy for Advanced Breast Cancer. , 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[93]  M. Espié,et al.  Ipatasertib plus paclitaxel versus placebo plus paclitaxel as first-line therapy for metastatic triple-negative breast cancer (LOTUS): a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial. , 2017, The Lancet. Oncology.

[94]  Paul Shapiro,et al.  Targeting the MAPK Signaling Pathway in Cancer: Promising Preclinical Activity with the Novel Selective ERK1/2 Inhibitor BVD-523 (Ulixertinib) , 2017, Molecular Cancer Therapeutics.

[95]  Michael E. Lassman,et al.  Oncolytic Virotherapy Promotes Intratumoral T Cell Infiltration and Improves Anti-PD-1 Immunotherapy , 2017, Cell.

[96]  Zachary L. Skidmore,et al.  A Phase II Trial of Neoadjuvant MK-2206, an AKT Inhibitor, with Anastrozole in Clinical Stage II or III PIK3CA-Mutant ER-Positive and HER2-Negative Breast Cancer , 2017, Clinical Cancer Research.

[97]  T. Shimoi,et al.  Phase 1 dose‐escalation study of single‐agent veliparib in Japanese patients with advanced solid tumors , 2017, Cancer science.

[98]  D. Kwapisz.  Cyclin-dependent kinase 4/6 inhibitors in breast cancer: palbociclib, ribociclib, and abemaciclib , 2017, Breast Cancer Research and Treatment.

[99]  Luis Manso,et al.  Polymorphisms associated with everolimus pharmacokinetics, toxicity and survival in metastatic breast cancer , 2017, PloS one.

[100]  G. Rowse,et al.  Abstract 31: Preclinical development of a novel biparatopic HER2 antibody with activity in low to high HER2 expressing cancers , 2017 .

[101]  Norikazu Masuda,et al.  Buparlisib plus fulvestrant versus placebo plus fulvestrant in postmenopausal, hormone receptor-positive, HER2-negative, advanced breast cancer (BELLE-2): a randomised, double-blind, placebo-controlled, phase 3 trial. , 2017, The Lancet. Oncology.

[102]  C. Denkert,et al.  Molecular alterations in triple-negative breast cancer—the road to new treatment strategies , 2017, The Lancet.

[103]  M. Robson,et al.  Olaparib for Metastatic Breast Cancer in Patients with a Germline BRCA Mutation , 2017, The New England journal of medicine.

[104]  P. Neven,et al.  MONARCH 2: Abemaciclib in Combination With Fulvestrant in Women With HR+/HER2- Advanced Breast Cancer Who Had Progressed While Receiving Endocrine Therapy. , 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[105]  David C. Smith,et al.  Phase I, Dose-Escalation, Two-Part Trial of the PARP Inhibitor Talazoparib in Patients with Advanced Germline BRCA1/2 Mutations and Selected Sporadic Cancers. , 2017, Cancer discovery.

[106]  S. Schnitt,et al.  Retinoblastoma (Rb) protein expression in triple-negative breast cancer. , 2017 .

[107]  S. Barni,et al.  A retrospective multicentric observational study of trastuzumab emtansine in HER2 positive metastatic breast cancer: a real-world experience , 2017, Oncotarget.

[108]  B. Taylor,et al.  AKT Inhibition in Solid Tumors With AKT1 Mutations. , 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[109]  E. Kohn,et al.  Safety and Clinical Activity of the Programmed Death-Ligand 1 Inhibitor Durvalumab in Combination With Poly (ADP-Ribose) Polymerase Inhibitor Olaparib or Vascular Endothelial Growth Factor Receptor 1-3 Inhibitor Cediranib in Women's Cancers: A Dose-Escalation, Phase I Study. , 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[110]  J. Baselga,et al.  Phase I Dose-Escalation Study of Taselisib, an Oral PI3K Inhibitor, in Patients with Advanced Solid Tumors. , 2017, Cancer discovery.

[111]  P. LoRusso,et al.  A Phase I/Ib Study of Enzalutamide Alone and in Combination with Endocrine Therapies in Women with Advanced Breast Cancer , 2017, Clinical Cancer Research.

[112]  A. Chinnaiyan,et al.  Precision medicine in pediatric oncology: Lessons learned and next steps , 2017, Pediatric blood & cancer.

[113]  Jürgen Unützer,et al.  A Tipping Point for Measurement-Based Care. , 2017, Psychiatric services.

[114]  R. Gray,et al.  E2112: randomized phase iii trial of endocrine therapy plus entinostat/placebo in patients with hormone receptor-positive advanced breast cancer , 2017, npj Breast Cancer.

[115]  D. Goldenberg,et al.  Synthetic Lethality Exploitation by an Anti–Trop-2-SN-38 Antibody–Drug Conjugate, IMMU-132, Plus PARP Inhibitors in BRCA1/2–wild-type Triple-Negative Breast Cancer , 2017, Clinical Cancer Research.

[116]  E. Winer,et al.  Phase II and Biomarker Study of Cabozantinib in Metastatic Triple‐Negative Breast Cancer Patients , 2016, The oncologist.

[117]  J. Baselga,et al.  A First-in-Human Phase I Study of the ATP-Competitive AKT Inhibitor Ipatasertib Demonstrates Robust and Safe Targeting of AKT in Patients with Solid Tumors. , 2017, Cancer discovery.

[118]  K. Gelmon,et al.  Palbociclib and Letrozole in Advanced Breast Cancer. , 2016, The New England journal of medicine.

[119]  Yi-long Wu,et al.  Phase I Study of the Pan-PI3K Inhibitor Buparlisib in Adult Chinese Patients with Advanced Solid Tumors. , 2016, Anticancer research.

[120]  J. Balko,et al.  Triple-negative breast cancer: challenges and opportunities of a heterogeneous disease , 2016, Nature Reviews Clinical Oncology.

[121]  E. Winer,et al.  Ribociclib as First-Line Therapy for HR-Positive, Advanced Breast Cancer. , 2016, The New England journal of medicine.

[122]  Gary D Bader,et al.  RB1 deficiency in triple-negative breast cancer induces mitochondrial protein translation. , 2016, The Journal of clinical investigation.

[123]  Lajos Pusztai,et al.  Pembrolizumab in Patients With Advanced Triple-Negative Breast Cancer: Phase Ib KEYNOTE-012 Study. , 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[124]  A. Garg,et al.  Correlative Analysis of Genetic Alterations and Everolimus Benefit in Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer: Results From BOLERO-2. , 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[125]  Matej Oresic,et al.  Metabolomics enables precision medicine: “A White Paper, Community Perspective” , 2016, Metabolomics.

[126]  P. Neven,et al.  Safety of everolimus plus exemestane in patients with hormone-receptor-positive, HER2-negative locally advanced or metastatic breast cancer progressing on prior non-steroidal aromatase inhibitors: primary results of a phase IIIb, open-label, single-arm, expanded-access multicenter trial (BALLET). , 2016, Annals of oncology : official journal of the European Society for Medical Oncology.

[127]  J. Winston,et al.  SIAH and EGFR, Two RAS Pathway Biomarkers, are Highly Prognostic in Locally Advanced and Metastatic Breast Cancer , 2016, EBioMedicine.

[128]  Ping Wang,et al.  Prognostic Role of Programmed Death Ligand-1 Expression in Breast Cancer: A Systematic Review and Meta-Analysis , 2016, Targeted Oncology.

[129]  Mehrdad Hamidi,et al.  Cubosomes: remarkable drug delivery potential. , 2016, Drug discovery today.

[130]  J. Grenier,et al.  A phase II trial of abiraterone acetate plus prednisone in patients with triple-negative androgen receptor positive locally advanced or metastatic breast cancer (UCBG 12-1). , 2016, Annals of oncology : official journal of the European Society for Medical Oncology.

[131]  R. Mangano,et al.  Phase 2 multicentre trial investigating intermittent and continuous dosing schedules of the poly(ADP-ribose) polymerase inhibitor rucaparib in germline BRCA mutation carriers with advanced ovarian and breast cancer , 2016, British Journal of Cancer.

[132]  Mechthild Krause,et al.  Radiation oncology in the era of precision medicine , 2016, Nature Reviews Cancer.

[133]  M. Kodaira,et al.  Safety and tolerability of AZD5363 in Japanese patients with advanced solid tumors , 2016, Cancer Chemotherapy and Pharmacology.

[134]  H. Rugo,et al.  Cyclin-Dependent Kinase 4/6 Inhibitors for the Treatment of Breast Cancer: A Review of Preclinical and Clinical Data. , 2016, Clinical breast cancer.

[135]  J. Grandis,et al.  Treatment of Triple-Negative Breast Cancer with TORC1/2 Inhibitors Sustains a Drug-Resistant and Notch-Dependent Cancer Stem Cell Population. , 2016, Cancer research.

[136]  O. Stål,et al.  Androgen receptor expression predicts beneficial tamoxifen response in oestrogen receptor-α-negative breast cancer , 2016, British Journal of Cancer.

[137]  D. Cescon,et al.  A phase I trial of ANG1/2-Tie2 inhibitor trebaninib (AMG386) and temsirolimus in advanced solid tumors (PJC008/NCI♯9041) , 2015, Investigational New Drugs.

[138]  S. Loi,et al.  Precision medicine for metastatic breast cancer—limitations and solutions , 2015, Nature Reviews Clinical Oncology.

[139]  A. Tolcher,et al.  A First-in-Human Phase I Study of the Oral p38 MAPK Inhibitor, Ralimetinib (LY2228820 Dimesylate), in Patients with Advanced Cancer , 2015, Clinical Cancer Research.

[140]  M. Moasser,et al.  The Evolving Landscape of HER2 Targeting in Breast Cancer. , 2015, JAMA oncology.

[141]  Yun-Ju Chen,et al.  Lapatinib increases motility of triple-negative breast cancer cells by decreasing miRNA-7 and inducing Raf-1/MAPK-dependent interleukin-6 , 2015, Oncotarget.

[142]  S. Loi,et al.  Palbociclib in Hormone-Receptor-Positive Advanced Breast Cancer. , 2015, The New England journal of medicine.

[143]  V. Adamo,et al.  Correction: Androgen Receptor (AR), E-Cadherin, and Ki-67 as Emerging Targets and Novel Prognostic Markers in Triple-Negative Breast Cancer (TNBC) Patients , 2015, PloS one.

[144]  E. Winer,et al.  Phase II study of tivantinib (ARQ 197) in patients with metastatic triple-negative breast cancer , 2015, Investigational New Drugs.

[145]  M. Kodaira,et al.  Phase 1 pharmacokinetic study of the oral pan-AKT inhibitor MK-2206 in Japanese patients with advanced solid tumors , 2015, Cancer Chemotherapy and Pharmacology.

[146]  Edmund A. Rossi,et al.  Trop-2 is a novel target for solid cancer therapy with sacituzumab govitecan (IMMU-132), an antibody-drug conjugate (ADC) , 2015, Oncotarget.

[147]  A. Stopeck,et al.  EMERGE: A Randomized Phase II Study of the Antibody-Drug Conjugate Glembatumumab Vedotin in Advanced Glycoprotein NMB-Expressing Breast Cancer. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[148]  C. Walsh.  Two decades beyond BRCA1/2: Homologous recombination, hereditary cancer risk and a target for ovarian cancer therapy. , 2015, Gynecologic oncology.

[149]  A. Jimeno,et al.  Apatinib: a promising oral antiangiogenic agent in the treatment of multiple solid tumors. , 2015, Drugs of today.

[150]  F. Collins,et al.  A new initiative on precision medicine. , 2015, The New England journal of medicine.

[151]  Agnieszka K. Witkiewicz,et al.  The history and future of targeting cyclin-dependent kinases in cancer therapy , 2015, Nature Reviews Drug Discovery.

[152]  E. Winer,et al.  Phase III study of iniparib plus gemcitabine and carboplatin versus gemcitabine and carboplatin in patients with metastatic triple-negative breast cancer. , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[153]  P. Neven,et al.  Everolimus plus exemestane for hormone-receptor-positive, human epidermal growth factor receptor-2-negative advanced breast cancer: overall survival results from BOLERO-2†. , 2014, Annals of oncology : official journal of the European Society for Medical Oncology.

[154]  P. Stephens,et al.  Triple-Negative Breast Cancer Patients Treated at MD Anderson Cancer Center in Phase I Trials: Improved Outcomes with Combination Chemotherapy and Targeted Agents , 2014, Molecular Cancer Therapeutics.

[155]  J. Bergh,et al.  LBA8A PHASE III RANDOMIZED, DOUBLE-BLIND, TRIAL COMPARING SORAFENIB PLUS CAPECITABINE VERSUS PLACEBO PLUS CAPECITABINE IN THE TREATMENT OF LOCALLY ADVANCED OR METASTATIC HER2-NEGATIVE BREAST CANCER (RESILIENCE) , 2014 .

[156]  R. Kurzrock,et al.  Dual inhibition of the vascular endothelial growth factor pathway: A phase 1 trial evaluating bevacizumab and AZD2171 (cediranib) in patients with advanced solid tumors , 2014, Cancer.

[157]  K. Lakshmaiah,et al.  Epigenetic therapy of cancer with histone deacetylase inhibitors. , 2014, Journal of cancer research and therapeutics.

[158]  M. Zucchetti,et al.  Phase I/IIa study evaluating the safety, efficacy, pharmacokinetics, and pharmacodynamics of lucitanib in advanced solid tumors. , 2014, Annals of oncology : official journal of the European Society for Medical Oncology.

[159]  Mallika Alvala,et al.  Piperlongumine, an alkaloid causes inhibition of PI3 K/Akt/mTOR signaling axis to induce caspase-dependent apoptosis in human triple-negative breast cancer cells , 2014, Apoptosis.

[160]  P. Sharma,et al.  PD-L1 Expression in Triple-Negative Breast Cancer , 2014, Cancer Immunology Research.

[161]  S. Vahdat,et al.  Patient Involvement in Health Care Decision Making: A Review , 2014, Iranian Red Crescent medical journal.

[162]  S. Adams,et al.  Phase 2 trial of everolimus and carboplatin combination in patients with triple negative metastatic breast cancer , 2014, Breast Cancer Research.

[163]  J. Reis-Filho,et al.  Tackling the Diversity of Triple-Negative Breast Cancer , 2013, Clinical Cancer Research.

[164]  Mark J. Ratain,et al.  Tumour heterogeneity in the clinic , 2013, Nature.

[165]  L. Hutchinson.  Breast cancer: BEATRICE bevacizumab trial—every cloud has a silver lining , 2013, Nature Reviews Clinical Oncology.

[166]  Andres Forero,et al.  Phase II Trial of Bicalutamide in Patients with Androgen Receptor–Positive, Estrogen Receptor–Negative Metastatic Breast Cancer , 2013, Clinical Cancer Research.

[167]  Levi A Garraway,et al.  Precision oncology: an overview. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[168]  Bohuslav Melichar,et al.  Randomized phase II, double-blind, placebo-controlled study of exemestane with or without entinostat in postmenopausal women with locally recurrent or metastatic estrogen receptor-positive breast cancer progressing on treatment with a nonsteroidal aromatase inhibitor. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[169]  L. Miele,et al.  Correlation of Notch1, pAKT and nuclear NF-κB expression in triple negative breast cancer. , 2013, American journal of cancer research.

[170]  S. Glück,et al.  Molecularly targeted therapies for metastatic triple-negative breast cancer , 2013, Breast Cancer Research and Treatment.

[171]  K. Gajiwala,et al.  Specific inhibition of Notch1 signaling enhances the antitumor efficacy of chemotherapy in triple negative breast cancer through reduction of cancer stem cells. , 2013, Cancer letters.

[172]  R. Tripaldi,et al.  Upregulation of Trop-2 quantitatively stimulates human cancer growth , 2013, Oncogene.

[173]  K. Pogoda,et al.  Analysis of pattern, time and risk factors influencing recurrence in triple-negative breast cancer patients , 2013, Medical Oncology.

[174]  Tyler T. Risom,et al.  Targeting Activated Akt with GDC-0068, a Novel Selective Akt Inhibitor That Is Efficacious in Multiple Tumor Models , 2013, Clinical Cancer Research.

[175]  Y. Pommier,et al.  Trapping of PARP1 and PARP2 by Clinical PARP Inhibitors. , 2012, Cancer research.

[176]  Lei He,et al.  PI3K inhibition impairs BRCA1/2 expression and sensitizes BRCA-proficient triple-negative breast cancer to PARP inhibition. , 2012, Cancer discovery.

[177]  Steven J. M. Jones,et al.  Comprehensive molecular portraits of human breast tumors , 2012, Nature.

[178]  M. Beckmann,et al.  A phase II trial to assess efficacy and safety of afatinib in extensively pretreated patients with HER2-negative metastatic breast cancer , 2012, Breast Cancer Research and Treatment.

[179]  R. Baskar,et al.  Cancer and Radiation Therapy: Current Advances and Future Directions , 2012, International journal of medical sciences.

[180]  M. Piccart,et al.  Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer. , 2012, The New England journal of medicine.

[181]  Thomas Helleday,et al.  The underlying mechanism for the PARP and BRCA synthetic lethality: Clearing up the misunderstandings , 2011, Molecular oncology.

[182]  Edward S. Kim,et al.  The BATTLE trial: personalizing therapy for lung cancer. , 2011, Cancer discovery.

[183]  E. Balslev,et al.  Effect of adding gefitinib to neoadjuvant chemotherapy in estrogen receptor negative early breast cancer in a randomized phase II trial , 2011, Breast Cancer Research and Treatment.

[184]  A. Jemal,et al.  Global Cancer Statistics , 2011 .

[185]  J. Bonneterre,et al.  Nasal septum perforation: a side effect of bevacizumab chemotherapy in breast cancer patients , 2010, British Journal of Cancer.

[186]  I. Larson,et al.  Phytantriol and glyceryl monooleate cubic liquid crystalline phases as sustained‐release oral drug delivery systems for poorly water‐soluble drugs II. In‐vivo evaluation , 2010 .

[187]  Gen Sheng Wu,et al.  Role of the Akt/mTOR survival pathway in cisplatin resistance in ovarian cancer cells. , 2010, Biochemical and biophysical research communications.

[188]  H. Willard,et al.  Genomic and personalized medicine: foundations and applications. , 2009, Translational research : the journal of laboratory and clinical medicine.

[189]  J. Ross,et al.  The HER-2 receptor and breast cancer: ten years of targeted anti-HER-2 therapy and personalized medicine. , 2009, The oncologist.

[190]  M. Swan.  Emerging Patient-Driven Health Care Models: An Examination of Health Social Networks, Consumer Personalized Medicine and Quantified Self-Tracking , 2009, International journal of environmental research and public health.

[191]  J. Crown,et al.  EGFR and HER-2 antagonists in breast cancer. , 2007, Anticancer research.

[192]  J. Woodcock,et al.  The Prospects for “Personalized Medicine” in Drug Development and Drug Therapy , 2007, Clinical pharmacology and therapeutics.

[193]  G. Graziani,et al.  Clinical perspectives of PARP inhibitors. , 2005, Pharmacological research.

[194]  Y. Tokuda,et al.  Combination of trastuzumab and vinorelbine in metastatic breast cancer. , 2003, Japanese journal of clinical oncology.

[195]  J. Mortimer,et al.  Phase II trial of weekly vinorelbine and trastuzumab as first-line therapy in patients with HER2(+) metastatic breast cancer. , 2002, The oncologist.

[196]  K. Mokbel.  The evolving role of aromatase inhibitors in breast cancer , 2002, International Journal of Clinical Oncology.

[197]  B. Leyland-Jones.  Trastuzumab: hopes and realities. , 2002, The Lancet. Oncology.

[198]  T. Fleming,et al.  Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. , 2001, The New England journal of medicine.

[199]  D. Slamon,et al.  Rationale for trastuzumab (Herceptin) in adjuvant breast cancer trials. , 2001, Seminars in oncology.

[200]  Christian A. Rees,et al.  Molecular portraits of human breast tumours , 2000, Nature.

[201]  D Tripathy,et al.  Phase II study of receptor-enhanced chemosensitivity using recombinant humanized anti-p185HER2/neu monoclonal antibody plus cisplatin in patients with HER2/neu-overexpressing metastatic breast cancer refractory to chemotherapy treatment. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[202]  N. Robert.  Clinical efficacy of tamoxifen. , 1997, Oncology.